You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTicagrelor
Accession NumberDB08816
TypeSmall Molecule
GroupsApproved
DescriptionTicagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
Structure
Thumb
Synonyms
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AZD 6140
AZD-6140
AZD6140
Brilinta
External Identifiers
  • AZD6140
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Brilintatablet60 mg/1oralAstra Zeneca Lp2015-09-04Not applicableUs
Brilintatablet90 mgoralAstrazeneca Canada Inc2011-06-01Not applicableCanada
Brilintatablet90 mg/1oralAstra Zeneca Lp2011-08-05Not applicableUs
Brilintatablet60 mgoralAstrazeneca Canada Inc2016-06-13Not applicableCanada
Brilintatablet90 mg/1oralCardinal Health2011-08-05Not applicableUs
Brilintatablet90 mg/1oralbryant ranch prepack2011-08-05Not applicableUs
BriliqueFilm-coated tablet90 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet60 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet90 mgOral use dose)Astra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet90 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet60 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet60 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet90 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet60 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet90 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet90 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueFilm-coated tablet60 mgOral useAstra Zeneca Ab2010-12-03Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BriliqueAstraZeneca
PossiaAstraZeneca
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIGLH0314RVC
CAS number274693-27-5
WeightAverage: 522.568
Monoisotopic: 522.186080514
Chemical FormulaC23H28F2N6O4S
InChI KeyInChIKey=OEKWJQXRCDYSHL-FNOIDJSQSA-N
InChI
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
IUPAC Name
(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
SMILES
CCCSC1=NC2=C(N=NN2[C@@H]2C[[email protected]](OCCO)[C@@H](O)[[email protected]]2O)C(N[C@@H]2C[[email protected]]2C2=CC(F)=C(F)C=C2)=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as triazolopyrimidines. These are polycyclic aromatic compounds containing triazole ring fused to a pyrimidine ring. Triazole is a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTriazolopyrimidines
Sub ClassNot Available
Direct ParentTriazolopyrimidines
Alternative Parents
Substituents
  • Triazolopyrimidine
  • Alkylarylthioether
  • Secondary aliphatic/aromatic amine
  • Halobenzene
  • Fluorobenzene
  • Aminopyrimidine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Cyclopentanol
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,3-triazole
  • Triazole
  • Cyclic alcohol
  • Azole
  • Secondary alcohol
  • 1,2-diol
  • Azacycle
  • Sulfenyl compound
  • Thioether
  • Secondary amine
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.
PharmacodynamicsPlasma concentrations of ticagrelor are slightly increased (12–23%) in elderly patients, women, patients of Asian ethnicity, and patients with mild hepatic impairment. They are decreased in patients that described themselves as 'coloured' and such with severe renal impairment. These differences are considered clinically irrelevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in patients with severe hepatic impairment.
Mechanism of actionLike the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19 (although it is not certain whether clopidogrel is significantly influenced by such variants).
Related Articles
AbsorptionAbsorbed quickly from the gut, the bioavailability being 36%.
Volume of distribution

The steady state volume of distribution of ticagrelor is 88 L.

Protein bindingBoth ticagrelor and AR-C124910XX are bound to plasma proteins (>99.7%), and both are pharmacologically active.
Metabolism

The main metabolite, AR-C124910XX, is formed quickly via CYP3A4 by de-hydroxyethylation at position 5 of the cyclopentane ring. The metabolite reaches 30–40% of ticagrelor's plasma concentrations.

Route of eliminationThe primary route of ticagrelor elimination is hepatic metabolism. When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (58% in feces, 26% in urine).
Half lifeTicagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours.
ClearanceNot Available
ToxicityBleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken. Other effects of overdose may include gastrointestinal effects (nausea, vomiting, diarrhea) or ventricular pauses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier-0.6719
Caco-2 permeable-0.5989
P-glycoprotein substrateSubstrate0.7626
P-glycoprotein inhibitor INon-inhibitor0.5907
P-glycoprotein inhibitor IINon-inhibitor0.9617
Renal organic cation transporterNon-inhibitor0.8606
CYP450 2C9 substrateNon-substrate0.7734
CYP450 2D6 substrateNon-substrate0.8048
CYP450 3A4 substrateSubstrate0.5057
CYP450 1A2 substrateNon-inhibitor0.5372
CYP450 2C9 inhibitorNon-inhibitor0.5767
CYP450 2D6 inhibitorNon-inhibitor0.8016
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.8744
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6243
Ames testNon AMES toxic0.5075
CarcinogenicityNon-carcinogens0.7777
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6308 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7742
hERG inhibition (predictor II)Non-inhibitor0.5914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral60 mg/1
Tabletoral60 mg
Tabletoral90 mg
Tabletoral90 mg/1
Film-coated tabletOral use60 mg
Film-coated tabletOral use90 mg
Film-coated tabletOral use dose)90 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2296665 No2008-06-102018-07-15Canada
CA2351709 No2010-04-062019-12-02Canada
CA2408596 No2010-12-212021-05-31Canada
US6251910 No1998-07-152018-07-15Us
US6525060 No1999-12-022019-12-02Us
US7250419 No1999-12-022019-12-02Us
US7265124 No2001-07-092021-07-09Us
US8425934 No2010-04-172030-04-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility10 μg/mLFDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.063 mg/mLALOGPS
logP2.31ALOGPS
logP2.28ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)2.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area138.44 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity142.13 m3·mol-1ChemAxon
Polarizability51.27 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Anil Shahaji Khile, “NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR.” U.S. Patent US20130165696, issued June 27, 2013.

US20130165696
General ReferencesNot Available
External Links
ATC CodesB01AC24
AHFS Codes
  • 20:12:18
PDB EntriesNot Available
FDA labelDownload (1.21 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabTicagrelor may increase the anticoagulant activities of Abciximab.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ticagrelor.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Ticagrelor.
AcenocoumarolTicagrelor may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Ticagrelor can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ticagrelor.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ticagrelor.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ticagrelor.
AlbendazoleThe serum concentration of Ticagrelor can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Ticagrelor can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ticagrelor.
AlectinibThe serum concentration of Ticagrelor can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Ticagrelor can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ticagrelor.
AlosetronThe metabolism of Alosetron can be decreased when combined with Ticagrelor.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Ticagrelor.
AlprostadilAlprostadil may increase the anticoagulant activities of Ticagrelor.
AmantadineThe serum concentration of Ticagrelor can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ticagrelor.
Aminohippuric acidThe serum concentration of Ticagrelor can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ticagrelor.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ticagrelor.
AmiodaroneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Ticagrelor.
AmitriptylineThe serum concentration of Ticagrelor can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Ticagrelor can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Ticagrelor can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ticagrelor.
AmsacrineThe serum concentration of Ticagrelor can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the anticoagulant activities of Ticagrelor.
AncrodTicagrelor may increase the anticoagulant activities of Ancrod.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ticagrelor.
Antithrombin III humanTicagrelor may increase the anticoagulant activities of Antithrombin III human.
ApixabanTicagrelor may increase the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Ticagrelor can be increased when it is combined with Aprepitant.
AprotininThe therapeutic efficacy of Ticagrelor can be decreased when used in combination with Aprotinin.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Ticagrelor.
ArdeparinTicagrelor may increase the anticoagulant activities of Ardeparin.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ticagrelor.
ArgatrobanTicagrelor may increase the anticoagulant activities of Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ticagrelor.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ticagrelor.
ArtemetherThe metabolism of Artemether can be decreased when combined with Ticagrelor.
AstemizoleThe serum concentration of Ticagrelor can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Atazanavir resulting in a loss in efficacy.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Ticagrelor.
AtenololThe serum concentration of Ticagrelor can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Ticagrelor can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ticagrelor.
AzelastineAzelastine may increase the anticoagulant activities of Ticagrelor.
AzelastineThe metabolism of Azelastine can be decreased when combined with Ticagrelor.
AzithromycinThe serum concentration of Ticagrelor can be increased when it is combined with Azithromycin.
BecaplerminTicagrelor may increase the anticoagulant activities of Becaplermin.
BenzocaineThe serum concentration of Ticagrelor can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Ticagrelor can be increased when it is combined with Bepridil.
BeraprostBeraprost may increase the anticoagulant activities of Ticagrelor.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ticagrelor.
BexaroteneThe serum concentration of Ticagrelor can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Ticagrelor.
BiperidenThe serum concentration of Ticagrelor can be increased when it is combined with Biperiden.
BivalirudinTicagrelor may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Boceprevir resulting in a loss in efficacy.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Ticagrelor.
BortezomibThe metabolism of Ticagrelor can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ticagrelor can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ticagrelor.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ticagrelor.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.
BromocriptineThe serum concentration of Ticagrelor can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ticagrelor.
BuprenorphineThe serum concentration of Ticagrelor can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Ticagrelor.
BupropionThe metabolism of Bupropion can be decreased when combined with Ticagrelor.
BuspironeThe serum concentration of Ticagrelor can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Ticagrelor can be increased when it is combined with Cabazitaxel.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Ticagrelor.
CaffeineThe serum concentration of Ticagrelor can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ticagrelor.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.
CandesartanThe serum concentration of Ticagrelor can be increased when it is combined with Candesartan.
CandesartanThe metabolism of Candesartan can be decreased when combined with Ticagrelor.
CangrelorCangrelor may increase the anticoagulant activities of Ticagrelor.
CaptoprilThe serum concentration of Ticagrelor can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Carbamazepine resulting in a loss in efficacy.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ticagrelor.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ticagrelor.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ticagrelor.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Ticagrelor.
CaspofunginThe serum concentration of Ticagrelor can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ticagrelor.
CeritinibThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ceritinib resulting in a loss in efficacy.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Ticagrelor.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ticagrelor.
CertoparinTicagrelor may increase the anticoagulant activities of Certoparin.
ChloroquineThe serum concentration of Ticagrelor can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Ticagrelor.
ChlorprothixeneThe serum concentration of Ticagrelor can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Ticagrelor can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Ticagrelor can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Ticagrelor can be increased when it is combined with Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Ticagrelor.
CimetidineThe serum concentration of Ticagrelor can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ticagrelor.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ticagrelor.
CiprofloxacinThe serum concentration of Ticagrelor can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Ticagrelor.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ticagrelor.
CitalopramThe serum concentration of Ticagrelor can be increased when it is combined with Citalopram.
Citric AcidTicagrelor may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Clarithromycin resulting in a loss in efficacy.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Ticagrelor.
ClemastineThe metabolism of Ticagrelor can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ticagrelor.
ClofazimineThe serum concentration of Ticagrelor can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ticagrelor.
ClomipramineThe serum concentration of Ticagrelor can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ticagrelor.
ClopidogrelClopidogrel may increase the anticoagulant activities of Ticagrelor.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ticagrelor.
ClotrimazoleThe metabolism of Ticagrelor can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ticagrelor.
CobicistatThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Cobicistat resulting in a loss in efficacy.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ticagrelor.
ColchicineThe serum concentration of Ticagrelor can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Ticagrelor can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Ticagrelor can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ticagrelor.
CrizotinibThe metabolism of Ticagrelor can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ticagrelor.
CyclophosphamideThe serum concentration of Ticagrelor can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.
CyclosporineThe serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.
Dabigatran etexilateTicagrelor may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ticagrelor.
DaclatasvirThe serum concentration of Ticagrelor can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Ticagrelor can be increased when it is combined with Dactinomycin.
DalteparinTicagrelor may increase the anticoagulant activities of Dalteparin.
DanaparoidTicagrelor may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ticagrelor.
DapsoneThe metabolism of Dapsone can be decreased when combined with Ticagrelor.
DarunavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Darunavir resulting in a loss in efficacy.
DasatinibThe serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Ticagrelor can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ticagrelor.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ticagrelor.
DeferasiroxThe serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Ticagrelor.
DelavirdineThe metabolism of Ticagrelor can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Ticagrelor can be increased when it is combined with Desipramine.
DesirudinTicagrelor may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Ticagrelor can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ticagrelor.
DextranTicagrelor may increase the anticoagulant activities of Dextran.
Dextran 40Ticagrelor may increase the anticoagulant activities of Dextran 40.
Dextran 70Ticagrelor may increase the anticoagulant activities of Dextran 70.
Dextran 75Ticagrelor may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Ticagrelor can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ticagrelor.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ticagrelor.
DiclofenacThe serum concentration of Ticagrelor can be increased when it is combined with Diclofenac.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ticagrelor.
DicoumarolTicagrelor may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ticagrelor.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ticagrelor.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ticagrelor.
DigoxinThe serum concentration of Ticagrelor can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Ticagrelor can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ticagrelor.
DiltiazemThe metabolism of Ticagrelor can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ticagrelor.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Ticagrelor.
DipyridamoleDipyridamole may increase the anticoagulant activities of Ticagrelor.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Ticagrelor.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ticagrelor.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ticagrelor.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Ticagrelor.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ticagrelor.
DonepezilThe metabolism of Donepezil can be decreased when combined with Ticagrelor.
DopamineThe metabolism of Dopamine can be decreased when combined with Ticagrelor.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ticagrelor.
DoxazosinThe serum concentration of Ticagrelor can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Ticagrelor can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Ticagrelor.
DoxorubicinThe serum concentration of Ticagrelor can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ticagrelor.
DoxycyclineThe metabolism of Ticagrelor can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ticagrelor.
DronedaroneThe metabolism of Ticagrelor can be decreased when combined with Dronedarone.
Edetic AcidTicagrelor may increase the anticoagulant activities of Edetic Acid.
EdoxabanTicagrelor may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Ticagrelor can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Ticagrelor can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ticagrelor.
EnalaprilThe serum concentration of Ticagrelor can be increased when it is combined with Enalapril.
EnoxaparinTicagrelor may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Enzalutamide resulting in a loss in efficacy.
EpinastineEpinastine may increase the anticoagulant activities of Ticagrelor.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ticagrelor.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ticagrelor.
EpoprostenolThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Ticagrelor.
ErgonovineThe serum concentration of Ticagrelor can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ticagrelor can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ticagrelor.
ErythromycinThe metabolism of Ticagrelor can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ticagrelor.
Eslicarbazepine acetateThe serum concentration of Ticagrelor can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ticagrelor.
EstramustineThe serum concentration of Ticagrelor can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Ticagrelor can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Ticagrelor.
EstroneThe serum concentration of Ticagrelor can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Ticagrelor.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ticagrelor.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ticagrelor.
Ethyl biscoumacetateTicagrelor may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacThe metabolism of Etodolac can be decreased when combined with Ticagrelor.
EtoposideThe serum concentration of Ticagrelor can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ticagrelor.
EtravirineThe serum concentration of Ticagrelor can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Ticagrelor.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ticagrelor.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ticagrelor.
FelodipineThe serum concentration of Ticagrelor can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Ticagrelor can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ticagrelor.
FexofenadineThe serum concentration of Ticagrelor can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Ticagrelor can be increased when it is combined with Fidaxomicin.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ticagrelor.
FluconazoleThe metabolism of Ticagrelor can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ticagrelor.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ticagrelor.
FluoxetineThe serum concentration of Ticagrelor can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Ticagrelor.
FlupentixolThe serum concentration of Ticagrelor can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Ticagrelor can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Ticagrelor can be increased when it is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Ticagrelor.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ticagrelor.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Ticagrelor.
FluvoxamineThe metabolism of Ticagrelor can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumTicagrelor may increase the anticoagulant activities of Fondaparinux sodium.
FormoterolThe metabolism of Formoterol can be decreased when combined with Ticagrelor.
FosamprenavirThe metabolism of Ticagrelor can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ticagrelor can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Fosphenytoin resulting in a loss in efficacy.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Ticagrelor.
Fusidic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Fusidic Acid.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Ticagrelor.
GefitinibThe serum concentration of Ticagrelor can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ticagrelor.
GenisteinThe serum concentration of Ticagrelor can be increased when it is combined with Genistein.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Ticagrelor.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Ticagrelor.
GlipizideThe metabolism of Glipizide can be decreased when combined with Ticagrelor.
GlyburideThe serum concentration of Ticagrelor can be increased when it is combined with Glyburide.
GlyburideThe metabolism of Glyburide can be decreased when combined with Ticagrelor.
GlycerolThe serum concentration of Ticagrelor can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Ticagrelor can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ticagrelor.
GrepafloxacinThe serum concentration of Ticagrelor can be increased when it is combined with Grepafloxacin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.
HaloperidolThe serum concentration of Ticagrelor can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Ticagrelor.
HeparinTicagrelor may increase the anticoagulant activities of Heparin.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ticagrelor.
HirulogTicagrelor may increase the anticoagulant activities of Hirulog.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Ticagrelor.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Ticagrelor.
HydrocortisoneThe serum concentration of Ticagrelor can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ticagrelor.
IbudilastIbudilast may increase the anticoagulant activities of Ticagrelor.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ticagrelor.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ticagrelor.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ticagrelor.
IdelalisibThe serum concentration of Ticagrelor can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Ticagrelor.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Ticagrelor.
IloprostIloprost may increase the anticoagulant activities of Ticagrelor.
IloprostThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Iloprost.
ImatinibThe metabolism of Ticagrelor can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ticagrelor.
ImipramineThe serum concentration of Ticagrelor can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ticagrelor.
IndinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Indinavir resulting in a loss in efficacy.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Ticagrelor.
indisulamThe metabolism of indisulam can be decreased when combined with Ticagrelor.
IndomethacinThe serum concentration of Ticagrelor can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Ticagrelor.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ticagrelor.
IsavuconazoniumThe metabolism of Ticagrelor can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Ticagrelor can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Itraconazole resulting in a loss in efficacy.
IvacaftorThe serum concentration of Ticagrelor can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ticagrelor can be increased when it is combined with Ivermectin.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ticagrelor.
KetamineThe serum concentration of Ticagrelor can be increased when it is combined with Ketamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Ticagrelor.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ticagrelor.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ticagrelor.
KetoconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ketoconazole resulting in a loss in efficacy.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Ticagrelor.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Ticagrelor.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ticagrelor.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ticagrelor.
LansoprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Ticagrelor can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ticagrelor.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Ticagrelor.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ticagrelor.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ticagrelor.
LepirudinTicagrelor may increase the anticoagulant activities of Lepirudin.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Ticagrelor.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ticagrelor.
LevofloxacinThe serum concentration of Ticagrelor can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ticagrelor.
LevothyroxineThe serum concentration of Ticagrelor can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Ticagrelor.
LidocaineThe serum concentration of Ticagrelor can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ticagrelor.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ticagrelor.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ticagrelor.
LiothyronineThe serum concentration of Ticagrelor can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Ticagrelor can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Ticagrelor can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ticagrelor.
LoperamideThe serum concentration of Ticagrelor can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.
LoratadineThe serum concentration of Ticagrelor can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Ticagrelor.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Ticagrelor.
LosartanThe serum concentration of Ticagrelor can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ticagrelor.
LovastatinThe metabolism of Ticagrelor can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Ticagrelor can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ticagrelor can be decreased when it is combined with Lumacaftor.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Ticagrelor.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ticagrelor.
MaprotilineThe serum concentration of Ticagrelor can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Ticagrelor can be increased when it is combined with Mebendazole.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Ticagrelor.
MefloquineThe serum concentration of Ticagrelor can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Ticagrelor can be increased when it is combined with Megestrol acetate.
MelatoninThe metabolism of Melatonin can be decreased when combined with Ticagrelor.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ticagrelor.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ticagrelor.
MeprobamateThe serum concentration of Ticagrelor can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ticagrelor.
MestranolThe metabolism of Mestranol can be decreased when combined with Ticagrelor.
MethadoneThe serum concentration of Ticagrelor can be increased when it is combined with Methadone.
MethadoneThe metabolism of Methadone can be decreased when combined with Ticagrelor.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ticagrelor.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ticagrelor.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ticagrelor.
MetoprololThe serum concentration of Ticagrelor can be increased when it is combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Ticagrelor.
MibefradilThe serum concentration of Ticagrelor can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Ticagrelor can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Ticagrelor can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ticagrelor.
MifepristoneThe metabolism of Ticagrelor can be decreased when combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Ticagrelor.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ticagrelor.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Ticagrelor.
MitomycinThe serum concentration of Ticagrelor can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Mitotane resulting in a loss in efficacy.
MitoxantroneThe serum concentration of Ticagrelor can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ticagrelor.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ticagrelor.
ModafinilThe serum concentration of Ticagrelor can be decreased when it is combined with Modafinil.
MontelukastThe metabolism of Montelukast can be decreased when combined with Ticagrelor.
MorphineThe serum concentration of Ticagrelor can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ticagrelor.
NadololThe serum concentration of Nadolol can be increased when it is combined with Ticagrelor.
NadroparinTicagrelor may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Ticagrelor can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ticagrelor.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ticagrelor.
NaltrexoneThe serum concentration of Ticagrelor can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Ticagrelor.
NaringeninThe serum concentration of Ticagrelor can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Ticagrelor.
NCX 4016NCX 4016 may increase the anticoagulant activities of Ticagrelor.
NefazodoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nefazodone resulting in a loss in efficacy.
NelfinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Ticagrelor.
NeostigmineThe serum concentration of Ticagrelor can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Ticagrelor can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Ticagrelor.
NevirapineThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nevirapine resulting in a loss in efficacy.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Ticagrelor.
NicardipineThe serum concentration of Ticagrelor can be increased when it is combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Ticagrelor.
NicotineThe metabolism of Nicotine can be decreased when combined with Ticagrelor.
NifedipineThe serum concentration of Ticagrelor can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ticagrelor.
NilotinibThe metabolism of Ticagrelor can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ticagrelor.
NimesulideNimesulide may increase the anticoagulant activities of Ticagrelor.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ticagrelor.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ticagrelor.
NisoldipineThe serum concentration of Ticagrelor can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Ticagrelor can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ticagrelor.
NorethisteroneThe serum concentration of Ticagrelor can be decreased when it is combined with Norethisterone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Ticagrelor.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ticagrelor.
OlaparibThe metabolism of Ticagrelor can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Ticagrelor.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ticagrelor.
OmeprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ticagrelor.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Ticagrelor.
OsimertinibThe serum concentration of Ticagrelor can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Ticagrelor.
OtamixabanTicagrelor may increase the anticoagulant activities of Otamixaban.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Ticagrelor.
P-NitrophenolThe serum concentration of Ticagrelor can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Ticagrelor can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Ticagrelor can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ticagrelor.
PantoprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ticagrelor.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Ticagrelor.
ParoxetineThe serum concentration of Ticagrelor can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.
PentobarbitalThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Pentobarbital resulting in a loss in efficacy.
Pentosan PolysulfateTicagrelor may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ticagrelor.
PerindoprilThe serum concentration of Ticagrelor can be increased when it is combined with Perindopril.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ticagrelor.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ticagrelor.
PhenindioneTicagrelor may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Phenobarbital resulting in a loss in efficacy.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Ticagrelor.
PhenprocoumonTicagrelor may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Ticagrelor.
PhenytoinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Phenytoin resulting in a loss in efficacy.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ticagrelor.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ticagrelor.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Ticagrelor.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ticagrelor.
Platelet Activating FactorThe serum concentration of Ticagrelor can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ticagrelor.
PosaconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Posaconazole resulting in a loss in efficacy.
PrasugrelPrasugrel may increase the anticoagulant activities of Ticagrelor.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Ticagrelor.
PravastatinThe serum concentration of Ticagrelor can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Ticagrelor can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ticagrelor.
PrednisoneThe serum concentration of Ticagrelor can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Primidone resulting in a loss in efficacy.
ProbenecidThe serum concentration of Ticagrelor can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Ticagrelor can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ticagrelor.
ProguanilThe metabolism of Proguanil can be decreased when combined with Ticagrelor.
PromazineThe metabolism of Promazine can be decreased when combined with Ticagrelor.
PromethazineThe serum concentration of Ticagrelor can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Ticagrelor can be increased when it is combined with Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Ticagrelor.
PropranololThe serum concentration of Ticagrelor can be increased when it is combined with Propranolol.
Protein CTicagrelor may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTicagrelor may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Ticagrelor can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ticagrelor.
QuazepamThe metabolism of Quazepam can be decreased when combined with Ticagrelor.
QuercetinThe serum concentration of Ticagrelor can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ticagrelor.
QuinacrineThe serum concentration of Ticagrelor can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Ticagrelor can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Ticagrelor can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Ticagrelor can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ticagrelor.
ReboxetineThe serum concentration of Ticagrelor can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Ticagrelor can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Ticagrelor can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Ticagrelor.
ResveratrolResveratrol may increase the anticoagulant activities of Ticagrelor.
ReviparinTicagrelor may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Ticagrelor.
RifabutinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Rifabutin resulting in a loss in efficacy.
RifampicinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Rifampicin resulting in a loss in efficacy.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ticagrelor.
RifapentineThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Rifapentine resulting in a loss in efficacy.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ticagrelor.
RilpivirineThe serum concentration of Ticagrelor can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ticagrelor.
RitonavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ritonavir resulting in a loss in efficacy.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Ticagrelor.
RivaroxabanTicagrelor may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ticagrelor.
RolapitantThe serum concentration of Ticagrelor can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ticagrelor.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Ticagrelor.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Ticagrelor.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ticagrelor.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ticagrelor.
SaquinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Saquinavir resulting in a loss in efficacy.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Ticagrelor.
SCH-530348SCH-530348 may increase the anticoagulant activities of Ticagrelor.
ScopolamineThe serum concentration of Ticagrelor can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Ticagrelor can be increased when it is combined with Selegiline.
SelegilineThe metabolism of Selegiline can be decreased when combined with Ticagrelor.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ticagrelor.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ticagrelor.
SertralineThe serum concentration of Ticagrelor can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Ticagrelor.
SevofluraneSevoflurane may increase the anticoagulant activities of Ticagrelor.
SildenafilThe metabolism of Ticagrelor can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ticagrelor.
SiltuximabThe serum concentration of Ticagrelor can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ticagrelor can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ticagrelor.
SirolimusThe serum concentration of Ticagrelor can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ticagrelor.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Ticagrelor.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ticagrelor.
SorafenibThe serum concentration of Ticagrelor can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ticagrelor.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ticagrelor.
SpironolactoneThe serum concentration of Ticagrelor can be increased when it is combined with Spironolactone.
SRT501SRT501 may increase the anticoagulant activities of Ticagrelor.
St. John's WortThe serum concentration of Ticagrelor can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Ticagrelor can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Ticagrelor can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Ticagrelor can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ticagrelor.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ticagrelor.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Ticagrelor.
SulfinpyrazoneThe serum concentration of Ticagrelor can be increased when it is combined with Sulfinpyrazone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ticagrelor.
SulfisoxazoleThe metabolism of Ticagrelor can be decreased when combined with Sulfisoxazole.
SulodexideTicagrelor may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Ticagrelor can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Ticagrelor can be increased when it is combined with Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Ticagrelor.
TacrineThe serum concentration of Ticagrelor can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Ticagrelor can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ticagrelor.
TamoxifenThe serum concentration of Ticagrelor can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ticagrelor.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Ticagrelor.
Taurocholic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ticagrelor.
TelaprevirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telaprevir resulting in a loss in efficacy.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Ticagrelor.
TelithromycinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telithromycin resulting in a loss in efficacy.
TelmisartanThe serum concentration of Ticagrelor can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Ticagrelor.
TemsirolimusThe serum concentration of Ticagrelor can be increased when it is combined with Temsirolimus.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Ticagrelor.
TerazosinThe serum concentration of Ticagrelor can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ticagrelor.
TerfenadineThe serum concentration of Ticagrelor can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Ticagrelor.
TesmilifeneTesmilifene may increase the anticoagulant activities of Ticagrelor.
TestosteroneThe serum concentration of Ticagrelor can be increased when it is combined with Testosterone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Ticagrelor.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Ticagrelor.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ticagrelor.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Ticagrelor.
TiclopidineTiclopidine may increase the anticoagulant activities of Ticagrelor.
TimololThe serum concentration of Timolol can be increased when it is combined with Ticagrelor.
TirofibanTirofiban may increase the anticoagulant activities of Ticagrelor.
TocilizumabThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Ticagrelor.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Ticagrelor.
TolvaptanThe serum concentration of Ticagrelor can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ticagrelor.
TorasemideThe metabolism of Torasemide can be decreased when combined with Ticagrelor.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ticagrelor.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Ticagrelor.
TranilastTranilast may increase the anticoagulant activities of Ticagrelor.
TrapidilTrapidil may increase the anticoagulant activities of Ticagrelor.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ticagrelor.
TrazodoneThe serum concentration of Ticagrelor can be decreased when it is combined with Trazodone.
TreprostinilThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Treprostinil.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ticagrelor.
TrifluoperazineThe serum concentration of Ticagrelor can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Ticagrelor can be increased when it is combined with Triflupromazine.
TriflusalTriflusal may increase the anticoagulant activities of Ticagrelor.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ticagrelor.
TrimethoprimThe serum concentration of Ticagrelor can be decreased when it is combined with Trimethoprim.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Ticagrelor.
TrimipramineThe serum concentration of Ticagrelor can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Ticagrelor.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Ticagrelor.
TroleandomycinThe serum concentration of Ticagrelor can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ticagrelor.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ticagrelor.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ticagrelor.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Ticagrelor.
ValsartanThe metabolism of Valsartan can be decreased when combined with Ticagrelor.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ticagrelor.
VenlafaxineThe metabolism of Ticagrelor can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ticagrelor.
VerapamilThe metabolism of Ticagrelor can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ticagrelor.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ticagrelor.
VinblastineThe serum concentration of Ticagrelor can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ticagrelor.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ticagrelor.
VincristineThe serum concentration of Ticagrelor can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Ticagrelor can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ticagrelor.
VorapaxarVorapaxar may increase the anticoagulant activities of Ticagrelor.
VoriconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Voriconazole resulting in a loss in efficacy.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Ticagrelor.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Ticagrelor.
WarfarinTicagrelor may increase the anticoagulant activities of Warfarin.
XimelagatranTicagrelor may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ticagrelor.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ticagrelor.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Ticagrelor.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ticagrelor.
ZileutonThe metabolism of Zileuton can be decreased when combined with Ticagrelor.
ZimelidineThe serum concentration of Ticagrelor can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Ticagrelor can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ticagrelor.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Ticagrelor.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Teng R, Oliver S, Hayes MA, Butler K: Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. doi: 10.1124/dmd.110.032250. Epub 2010 Jun 15. [PubMed:20551239 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on August 01, 2011 15:32 / Updated on September 28, 2016 02:27